Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.36 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11927507 | 0.79 | NEK2 (0.47) | CHRM2OPRM1OTUD7B | |
| SCHEMBL18213841 | 0.77 | CYP3A4 (0.36) | — | |
| SCHEMBL8230583 | 0.73 | CRBN (0.45) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL13924898 | 0.72 | KMT2A (0.36) | — | |
| SCHEMBL30832405 | 0.72 | PDE7A (0.33) | — | |
| SCHEMBL22804814 | 0.72 | CRBN (0.32) | — | |
| SCHEMBL21341554 | 0.72 | GRIN2D (0.39) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL12312682 | 0.71 | GRIN2D (0.36) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL22256974 | 0.71 | IDO1 (0.41) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL25990796 | 0.71 | GRIN2D (0.41) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796260-B2 | Imidazobenzazepine CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20140128375-A1 | BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2014-05-08 | — | — | US | disclosed |
| US-20120065190-A1 | BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2012-03-15 | — | — | US | disclosed |
| US-20100324023-A1 | IMIDAZOBENZAZEPINE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128375-A1 | BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS | BDKRB1, BDKRB2, CALCRL | GRIN2D 426/4885GRIN3B 246/4885CHRM2 117/4885 |
| US-20100324023-A1 | IMIDAZOBENZAZEPINE CGRP RECEPTOR ANTAGONISTS | BDKRB1, CCKBR, CALCRL | GRIN2D 497/4885GRIN3B 280/4885CHRM2 212/4885 |
| US-20120065190-A1 | BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS | BDKRB1, BDKRB2, CALCRL | GRIN2D 426/4885GRIN3B 246/4885CHRM2 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.